Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance
An antibody–drug conjugate (ADC) is an advanced chemotherapeutic option with immense promises in treating many tumor. They are designed to selectively attack and kill neoplastic cells with minimal toxicity to normal tissues. ADCs are complex engineered immunoconjugates that comprise a monoclonal ant...
Gespeichert in:
| Veröffentlicht in: | Clinical & translational oncology 2022-03, Vol.24 (3), p.407-431 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 431 |
|---|---|
| container_issue | 3 |
| container_start_page | 407 |
| container_title | Clinical & translational oncology |
| container_volume | 24 |
| creator | Murali, M. Kumar, A. R. Nair, B. Pavithran, K. Devan, A. R. Pradeep, G. K. Nath, L. R. |
| description | An antibody–drug conjugate (ADC) is an advanced chemotherapeutic option with immense promises in treating many tumor. They are designed to selectively attack and kill neoplastic cells with minimal toxicity to normal tissues. ADCs are complex engineered immunoconjugates that comprise a monoclonal antibody for site-directed delivery and cytotoxic payload for targeted destruction of malignant cells. Therefore, it enables the reduction of off-target toxicities and enhances the therapeutic index of the drug. Hepatocellular carcinoma (HCC) is a solid tumor that shows high heterogeneity of molecular phenotypes and is considered the second most common cause of cancer-related death. Studies show enormous potential for ADCs targeting GPC3 and CD24 and other tumor-associated antigens in HCC with their high, selective expression and show potential outputs in preclinical evaluations. The review mainly highlights the preclinical evaluation of different antigen-targeted ADCs such as MetFab-DOX, Anti-c-Met IgG-OXA, Anti CD 24, ANC–HN-01, G7mab-DOX, hYP7-DCand hYP7-PC, Anti-CD147 ILs-DOX and AC133-vcMMAF against hepatocellular carcinoma and its future relevance.
Graphic abstract |
| doi_str_mv | 10.1007/s12094-021-02707-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2578777520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2578777520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-df6224a8c1daf6cb7c1f0f6b5b7a5e1d2cab022e3425a7132650643d6db8adcd3</originalsourceid><addsrcrecordid>eNp9kL1uFDEUhS1ERELgBSiQS5oB_4ztXboo4k-KlCZIdNYd-87Eq1nP4B-kVPAOvCFPEoddUlJYto7PObr3I-QVZ285Y-Zd5oJt-44J3o5hplNPyBnX220nmVJPj2_Wb76dkuc571hTNefPyKns1VYZqc_Iz4tYwrD4uz-_fvtUJ-qWuKsTFKSQaYE0YUFPyy0mWLGW4DKFCULMhd7iCmVxOM91hkQdJBfisof3dE3o5hCDg5nmUn3AloqePooJZ_wB0eELcjLCnPHl8T4nXz9-uLn83F1df_pyeXHVOdmb0vlRC9HDxnEPo3aDcXxkox7UYEAh98LBwIRA2QsFhkuhFdO99NoPG_DOy3Py5tC7puV7xVzsPuSH0SHiUrMVymyMMUqwZhUHq0tLzglHu6awh3RnObMP4O0BvG3g7V_wVrXQ62N_HfboHyP_SDeDPBhy-4oTJrtbaopt5__V3gPyo5Ne</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2578777520</pqid></control><display><type>article</type><title>Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Murali, M. ; Kumar, A. R. ; Nair, B. ; Pavithran, K. ; Devan, A. R. ; Pradeep, G. K. ; Nath, L. R.</creator><creatorcontrib>Murali, M. ; Kumar, A. R. ; Nair, B. ; Pavithran, K. ; Devan, A. R. ; Pradeep, G. K. ; Nath, L. R.</creatorcontrib><description>An antibody–drug conjugate (ADC) is an advanced chemotherapeutic option with immense promises in treating many tumor. They are designed to selectively attack and kill neoplastic cells with minimal toxicity to normal tissues. ADCs are complex engineered immunoconjugates that comprise a monoclonal antibody for site-directed delivery and cytotoxic payload for targeted destruction of malignant cells. Therefore, it enables the reduction of off-target toxicities and enhances the therapeutic index of the drug. Hepatocellular carcinoma (HCC) is a solid tumor that shows high heterogeneity of molecular phenotypes and is considered the second most common cause of cancer-related death. Studies show enormous potential for ADCs targeting GPC3 and CD24 and other tumor-associated antigens in HCC with their high, selective expression and show potential outputs in preclinical evaluations. The review mainly highlights the preclinical evaluation of different antigen-targeted ADCs such as MetFab-DOX, Anti-c-Met IgG-OXA, Anti CD 24, ANC–HN-01, G7mab-DOX, hYP7-DCand hYP7-PC, Anti-CD147 ILs-DOX and AC133-vcMMAF against hepatocellular carcinoma and its future relevance.
Graphic abstract</description><identifier>ISSN: 1699-048X</identifier><identifier>EISSN: 1699-3055</identifier><identifier>DOI: 10.1007/s12094-021-02707-5</identifier><identifier>PMID: 34595736</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Carcinoma, Hepatocellular - drug therapy ; Drug Evaluation, Preclinical ; Humans ; Immunoconjugates - therapeutic use ; Liver Neoplasms - drug therapy ; Medicine ; Medicine & Public Health ; Oncology ; Review Article</subject><ispartof>Clinical & translational oncology, 2022-03, Vol.24 (3), p.407-431</ispartof><rights>Federación de Sociedades Españolas de Oncología (FESEO) 2021</rights><rights>2021. Federación de Sociedades Españolas de Oncología (FESEO).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-df6224a8c1daf6cb7c1f0f6b5b7a5e1d2cab022e3425a7132650643d6db8adcd3</citedby><cites>FETCH-LOGICAL-c347t-df6224a8c1daf6cb7c1f0f6b5b7a5e1d2cab022e3425a7132650643d6db8adcd3</cites><orcidid>0000-0002-7726-7219</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12094-021-02707-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12094-021-02707-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34595736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murali, M.</creatorcontrib><creatorcontrib>Kumar, A. R.</creatorcontrib><creatorcontrib>Nair, B.</creatorcontrib><creatorcontrib>Pavithran, K.</creatorcontrib><creatorcontrib>Devan, A. R.</creatorcontrib><creatorcontrib>Pradeep, G. K.</creatorcontrib><creatorcontrib>Nath, L. R.</creatorcontrib><title>Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance</title><title>Clinical & translational oncology</title><addtitle>Clin Transl Oncol</addtitle><addtitle>Clin Transl Oncol</addtitle><description>An antibody–drug conjugate (ADC) is an advanced chemotherapeutic option with immense promises in treating many tumor. They are designed to selectively attack and kill neoplastic cells with minimal toxicity to normal tissues. ADCs are complex engineered immunoconjugates that comprise a monoclonal antibody for site-directed delivery and cytotoxic payload for targeted destruction of malignant cells. Therefore, it enables the reduction of off-target toxicities and enhances the therapeutic index of the drug. Hepatocellular carcinoma (HCC) is a solid tumor that shows high heterogeneity of molecular phenotypes and is considered the second most common cause of cancer-related death. Studies show enormous potential for ADCs targeting GPC3 and CD24 and other tumor-associated antigens in HCC with their high, selective expression and show potential outputs in preclinical evaluations. The review mainly highlights the preclinical evaluation of different antigen-targeted ADCs such as MetFab-DOX, Anti-c-Met IgG-OXA, Anti CD 24, ANC–HN-01, G7mab-DOX, hYP7-DCand hYP7-PC, Anti-CD147 ILs-DOX and AC133-vcMMAF against hepatocellular carcinoma and its future relevance.
Graphic abstract</description><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Drug Evaluation, Preclinical</subject><subject>Humans</subject><subject>Immunoconjugates - therapeutic use</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Review Article</subject><issn>1699-048X</issn><issn>1699-3055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kL1uFDEUhS1ERELgBSiQS5oB_4ztXboo4k-KlCZIdNYd-87Eq1nP4B-kVPAOvCFPEoddUlJYto7PObr3I-QVZ285Y-Zd5oJt-44J3o5hplNPyBnX220nmVJPj2_Wb76dkuc571hTNefPyKns1VYZqc_Iz4tYwrD4uz-_fvtUJ-qWuKsTFKSQaYE0YUFPyy0mWLGW4DKFCULMhd7iCmVxOM91hkQdJBfisof3dE3o5hCDg5nmUn3AloqePooJZ_wB0eELcjLCnPHl8T4nXz9-uLn83F1df_pyeXHVOdmb0vlRC9HDxnEPo3aDcXxkox7UYEAh98LBwIRA2QsFhkuhFdO99NoPG_DOy3Py5tC7puV7xVzsPuSH0SHiUrMVymyMMUqwZhUHq0tLzglHu6awh3RnObMP4O0BvG3g7V_wVrXQ62N_HfboHyP_SDeDPBhy-4oTJrtbaopt5__V3gPyo5Ne</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Murali, M.</creator><creator>Kumar, A. R.</creator><creator>Nair, B.</creator><creator>Pavithran, K.</creator><creator>Devan, A. R.</creator><creator>Pradeep, G. K.</creator><creator>Nath, L. R.</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7726-7219</orcidid></search><sort><creationdate>20220301</creationdate><title>Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance</title><author>Murali, M. ; Kumar, A. R. ; Nair, B. ; Pavithran, K. ; Devan, A. R. ; Pradeep, G. K. ; Nath, L. R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-df6224a8c1daf6cb7c1f0f6b5b7a5e1d2cab022e3425a7132650643d6db8adcd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Drug Evaluation, Preclinical</topic><topic>Humans</topic><topic>Immunoconjugates - therapeutic use</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Review Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murali, M.</creatorcontrib><creatorcontrib>Kumar, A. R.</creatorcontrib><creatorcontrib>Nair, B.</creatorcontrib><creatorcontrib>Pavithran, K.</creatorcontrib><creatorcontrib>Devan, A. R.</creatorcontrib><creatorcontrib>Pradeep, G. K.</creatorcontrib><creatorcontrib>Nath, L. R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical & translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murali, M.</au><au>Kumar, A. R.</au><au>Nair, B.</au><au>Pavithran, K.</au><au>Devan, A. R.</au><au>Pradeep, G. K.</au><au>Nath, L. R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance</atitle><jtitle>Clinical & translational oncology</jtitle><stitle>Clin Transl Oncol</stitle><addtitle>Clin Transl Oncol</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>24</volume><issue>3</issue><spage>407</spage><epage>431</epage><pages>407-431</pages><issn>1699-048X</issn><eissn>1699-3055</eissn><abstract>An antibody–drug conjugate (ADC) is an advanced chemotherapeutic option with immense promises in treating many tumor. They are designed to selectively attack and kill neoplastic cells with minimal toxicity to normal tissues. ADCs are complex engineered immunoconjugates that comprise a monoclonal antibody for site-directed delivery and cytotoxic payload for targeted destruction of malignant cells. Therefore, it enables the reduction of off-target toxicities and enhances the therapeutic index of the drug. Hepatocellular carcinoma (HCC) is a solid tumor that shows high heterogeneity of molecular phenotypes and is considered the second most common cause of cancer-related death. Studies show enormous potential for ADCs targeting GPC3 and CD24 and other tumor-associated antigens in HCC with their high, selective expression and show potential outputs in preclinical evaluations. The review mainly highlights the preclinical evaluation of different antigen-targeted ADCs such as MetFab-DOX, Anti-c-Met IgG-OXA, Anti CD 24, ANC–HN-01, G7mab-DOX, hYP7-DCand hYP7-PC, Anti-CD147 ILs-DOX and AC133-vcMMAF against hepatocellular carcinoma and its future relevance.
Graphic abstract</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>34595736</pmid><doi>10.1007/s12094-021-02707-5</doi><tpages>25</tpages><orcidid>https://orcid.org/0000-0002-7726-7219</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1699-048X |
| ispartof | Clinical & translational oncology, 2022-03, Vol.24 (3), p.407-431 |
| issn | 1699-048X 1699-3055 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2578777520 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Carcinoma, Hepatocellular - drug therapy Drug Evaluation, Preclinical Humans Immunoconjugates - therapeutic use Liver Neoplasms - drug therapy Medicine Medicine & Public Health Oncology Review Article |
| title | Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T01%3A17%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%E2%80%93drug%20conjugate%20as%20targeted%20therapeutics%20against%20hepatocellular%20carcinoma:%20preclinical%20studies%20and%20clinical%20relevance&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=Murali,%20M.&rft.date=2022-03-01&rft.volume=24&rft.issue=3&rft.spage=407&rft.epage=431&rft.pages=407-431&rft.issn=1699-048X&rft.eissn=1699-3055&rft_id=info:doi/10.1007/s12094-021-02707-5&rft_dat=%3Cproquest_cross%3E2578777520%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2578777520&rft_id=info:pmid/34595736&rfr_iscdi=true |